Revvity reported second quarter 2026 revenue of $730 million and GAAP EPS of $0.48. The company entered a definitive agreement to divest its China Immunodiagnostics business for up to $200 million, with closing expected by the end of 2027. Pro forma results exclude this unit, showing Q2 revenue of $711 million and adjusted EPS of $1.41. Full-year 2026 pro forma guidance was raised to forecast revenue between $2.83 billion and $2.86 billion and adjusted EPS between $5.30 and $5.40. Revvity operates in the health science industry, providing technologies and services for discovery, development, diagnosis, and cure.